Targeted delivery of biological agents to atherosclerotic plaques may provide a novel treatment and/or useful tool for imaging of atherosclerosis in vivo. However, there are no known viral vectors that possess the desired tropism. Two plaque-targeting peptides, CAPGPSKSC (CAP) and CNHRYMQMC (CNH) were inserted into the capsid of adeno-associated virus 2 (AAV2) to assess vector retargeting. AAV2-CNH produced significantly higher levels of transduction than unmodified AAV2 in human, murine and rat endothelial cells, whereas transduction of nontarget HeLa cells was unaltered. Transduction studies and surface plasmon resonance suggest that AAV2-CNH uses membrane type 1 matrix metalloproteinase as a surface receptor.
Introduction
Cardiovascular disease is the leading cause of death in the Western world, and in approximately 75% of cases, atherosclerosis is the main contributing factor (www.heartstats.org). The rupture of unstable atherosclerotic plaques can result in the formation of occlusive thrombi that can block arteries and can cause myocardial infarction. No efficient pharmacological agents have been developed to stabilize vulnerable plaques, therefore there is a need to develop a novel form of treatment and tools for studying rupture prone plaques. Gene delivery could provide a promising new approach to this serious clinical problem. Local gene delivery using adenoviral vectors applied transluminally has been shown to alter plaque composition in animal models [1] [2] [3] but requires undesirable surgery. Genetic interventions aiming to prevent rupture of unstable atherosclerotic plaques are likely to be most effective using a vector that can provide transgene expression specifically in the plaque following intravenous injection. This is due to the need for an adequate dose of therapeutic agent to be provided locally to act on the appropriate target cells. As yet no vectors that specifically target atherosclerotic plaques have been identified, however methods of targeting vectors to alternative cell types are now reasonably well established and may be applied to overcome this problem. To produce a viral vector with a highly selective tropism, genetic modification of the virus capsid can be used to both detarget the virus from its native tropism and retarget it to a novel receptor on an alternative cell type. 4 Adeno-associated virus 2 (AAV2) has been investigated for many gene therapy applications and it has been shown to have many desirable properties, such as an ability to produce relatively long-term transgene expression in vivo. However, systemic administration of AAV2 results in a very low level of transduction of vascular cells 5, 6 and the majority of the virus is found in the liver and spleen. 7, 8 The primary receptor for AAV2 is heparan sulphate proteoglycan (HSPG). 9 Insertion of targeting peptides into the HSPG binding site (after residue 587) ( Figure 1a ) has been shown to reduce the natural tropism of the virus and retarget it to alternative cell types in vitro and in vivo. 5, 6, [10] [11] [12] Therefore a single modification can both detarget and retarget the vector, although the efficiency of this is peptide dependent.
Molecules that are selectively upregulated on the surface of plaques could potentially function as receptors for gene therapy vectors. Peptides that target these molecules could be utilized to exploit these differences and target viral vectors to atherosclerotic plaques, potentially with a high degree of selectivity. Liu et al. 13 identified 103 plaque-targeting peptides by performing phage display in a mouse model of atherosclerosis. The most commonly occurring peptide motif ( P /Q G / Y PS K / R SC) was found at a frequency of 9.7% and is contained within the CAPGPSKSC (CAP) peptide. This peptide was shown not to bind healthy murine aortas, but did bind to human arterial atherosclerotic lesions ex vivo, suggesting that the peptide has a plaque-specific targeting capacity. 13 Glucose-regulated protein 78 (Grp78) (also known as BiP) an endoplasmic reticulum (ER) chaperone protein, was identified as the putative receptor for this peptide. 13 Grp78 is constitutively expressed in the ER of almost all cell types 14 and has been shown to be expressed on the surface of cells under stress. 15 It is expressed on the endothelium of plaques and on the surface of monocytes and foam cells within plaques 16, 17 so it could potentially act as a receptor for a plaque targeted vector.
A second peptide motif (CN Q / H R H / Y MQMSC) that occurred at a relatively high frequency (1.8%) was contained in the peptide CNHRYMQMC (CNH). This peptide is of particular interest as BLAST scanning showed it has homology to tissue inhibitor of matrix metalloproteinases 2 (TIMP2). 13 TIMPs are naturally occurring inhibitors of matrix metalloproteinases (MMPs). Many MMPs are known to be expressed in atherosclerotic plaques where they have a role in vascular remodelling, SMC migration, neointima formation, angiogenesis and plaque disruption. [18] [19] [20] [21] [22] [23] [24] [25] As TIMP2 is known to interact with membrane type 1 MMP (MT1-MMP) at the cell surface, it is possible that the TIMP2 homologous peptide CNH may also bind to MT1-MMP. TIMP2 competitively inhibited the binding of the CNH peptide to human umbilical vein endothelial cells (HUVEC), suggesting that the peptide binds to a TIMP2 binding protein. 13 In order to develop a viral vector with improved uptake into regions of atherosclerotic vasculature the two plaque-targeting peptides CAP and CNH were genetically engineered into the HSPG binding site of the AAV2 capsid. The transduction profiles of the vectors were compared in vitro and their targeting capacity was analysed in vivo in a mouse model of atherosclerosis.
Results

In vitro characterization of peptide-modified AAV2 vectors
Since we have previously demonstrated targeting of peptide modified AAV2 vectors in vitro and in vivo, 5, 11, 12 the CAP and CNH peptides were incorporated into the capsid of AAV2 after residue 587 (Figure 1a ). Models predicting possible structures formed by the peptide insertions (with and without the formation of a disulphide bond) were produced (Figures 1b and c) . To examine the effects of the peptide insertions on virus infectivity and assess species cross-reactivity, infections of primary human saphenous vein endothelial cells (HSVEC), rat and mouse vascular endothelial cell lines were performed. As a control, infections were also carried out in nontarget HeLa cells, a nonvascular cell line that does not express the putative receptors for the CAP peptide (Grp78) 26 and CNH peptide (MT1-MMP). 27 Both Grp78 and MT1-MMP levels were higher in HSVEC compared to HeLa cells evaluated by Taqman QRT-PCR (not shown). In HeLa cells there was no significant difference in transduction between the peptide-modified AAV2 vectors and control AAV2 (Figure 2 ). Additionally, no increased transduction was observed in human monocytes or vascular smooth muscle cells (not shown).
In all the endothelial cell lines tested AAV2-CNH produced significantly higher levels of transduction than control AAV2. However, AAV2-CAP only produced a significantly higher level of transduction in RGE cells ( Figure 2 ).
Heparin binding of peptide-modified AAV2 based vectors
In vivo, the low level of transduction of endothelial cells is in part thought to be due to the virus being Targeting AAV2 to atherosclerotic plaques K White et al sequestered in the extracellular matrix by binding to HSPG. 28 To determine whether insertion of the peptides into the capsid of AAV2 affects the ability of the virus to bind HSPG, binding to the receptor analogue heparin was evaluated by heparin affinity chromatography ( Figure 3a ) Both peptide-modified viruses and control AAV2-RC bound to the column and were eluted in the first elution with 1 M NaCl, suggesting that both the modified vectors still bind heparin. However, the majority of AAV2-CAP and AAV2-CNH was not detected in any of the elution fractions, whereas approximately 100% of AAV2-RC was recovered.
To determine whether heparin binding affects infectivity of the viruses, infection of the mouse endothelial cell lines was repeated in the presence of soluble heparin (Figures 3b and c) . In both cell types reduced levels of infection were seen with AAV2-RC, AAV2-CAP and AAV2-CNH in the presence of heparin, suggesting both AAV2-CAP and AAV2-CNH maintain the ability to bind to HSPG.
MT1-MMP may act as the receptor for AAV2-CNH
The CNH peptide has significant sequence homology to TIMP2, so it is possible that the CNH peptide binds MT1-MMP. 13 To determine if CNH uses MT1-MMP as a receptor, AAV2-CNH infections were performed in the human fibrosarcoma cell line HT1080 stably transfected with MT1-MMP and control untransfected cells that express a low level of MT1-MMP.
29 AAV2-CNH produced a significantly higher level (seven-fold) of transduction in cells overexpressing MT1-MMP, whereas there was no significant difference in the transduction of AAV2-RC (Figure 4a ), suggesting that AAV2-CNH uses MT1-MMP as a receptor.
The interaction between MT1-MMP and AAV2-CNH was also analysed using surface plasmon resonance. MT1-MMP was immobilized on a biosensor chip and TIMP2, AAV2-RC or AAV2-CNH were injected over the chip ( Figure 4 ). While the positive control TIMP2 was 
Effect of proteasome inhibitors on transduction of peptide-modified AAV2 vectors
AAV2 transduction has been shown to be limited by the proteasome in some cell types including epithelial cells and vascular cells. 28, [30] [31] [32] Some peptide-modified AAV2 vectors have been shown to traffic to the nucleus by alternative pathways that are not sensitive to degradation by the proteasome. 11, 12 To determine whether the proteasome affects AAV2-CAP and AAV2-CNH, infections of SVEC 4-10 and IP-1B cells were performed in the presence of the proteasome inhibitors MG132 (4 mM) and LnLL (40 mM) ( Figure 5 ). Both AAV2-RC and AAV2-CAP transduction was significantly enhanced by both proteasome inhibitors in both cell lines, whereas AAV2-CNH transduction was only significantly increased by MG132 in SVEC 4-10 cells and in comparison to AAV2-CAP and AAV2-RC this was only a mild effect. Therefore, the insertion of the CNH peptide into the AAV2 platform may alter both the receptor and the trafficking mechanism of the virus, whereas AAV2-CAP traffics to the nucleus via the same proteasome sensitive pathway as control AAV2, which may potentially limit the transgene expression produced by this vector.
Biodistribution profiles of the AAV2 based vectors in vivo
The in vivo targeting capacity of the vectors was tested in ApoEÀ/À mice that have been shown to develop atherosclerotic plaques in the brachiocephalic artery (BCA).
33 AAV2 vectors (6 Â 10 9 gp) were injected into the tail vein of ApoEÀ/À mice. Twenty-eight days later Targeting AAV2 to atherosclerotic plaques K White et al DNA was extracted from tissues and used as a template for real-time PCR to produce biodistribution profiles of the viruses ( Figure 6 ). The results showed that for both AAV2-CAP and AAV2-CNH there was a 10-to 100-fold increase in the amount of vector detected in the BCA and aorta compared to the amount of unmodified AAV2 detected. In addition to this retargeting, both modified vectors were detected at a lower level than control virus in all other tissues examined, suggesting that the peptides also have a detargeting effect on the natural tropism of the virus. Finally, we confirmed the selectivity of increased uptake into the disease vasculature. AAV-CAP and AAV2-RC were injected into fat-fed and nondiseased mice and the ratio of organ targeting for AAV-CAP/AAV-RC calculated. As seen in Figure 7 , AAV-CAP accumulation was selective for diseased blood vessels and did not occur for control AAV2-RC.
Discussion
This study describes the production and characterization of AAV2 based vectors containing atherosclerotic plaque targeting peptides CAP and CNH. In vitro and in vivo analysis of the tropism of the vectors was performed to determine the targeting capacity of the peptides inserted into the AAV vector platform.
The basic transduction profiles of the AAV2 vectors show that AAV2-CNH seems to target endothelial cells whereas AAV2-CAP only produced significantly higher transduction levels than the control virus in RGE cells.
Despite the insertion of the peptides into the HSPG binding site of the AAV2 capsid, binding of the viruses to heparin columns and in vitro heparin competition experiments suggest that the ability of the viruses to bind 9 gp) were injected into the tail vein of mice, which were killed 28 days later. DNA was extracted from tissues and used as a template for real-time PCR with primers that bind the eGFP transgene. Graph shows the fold change in the ratio of AAV-CAP to AAV-RC accumulation in tissues and organs of diseased or nondiseased mice. n ¼ 3 per group.
Targeting AAV2 to atherosclerotic plaques K White et al heparin and utilize it as a receptor has not been ablated. Binding is due to an electrostatic interaction between positively charged residues in the heparin binding site and negatively charged HSPG, 34 so the charge of the inserted peptide is thought to be an important determinant of whether heparin binding is maintained. 6, [35] [36] [37] Characterization of an AAV2 library with random 7-mer peptides inserted after residue 587 suggests that positively charged peptides mediate the formation of an HSPG binding site whereas negatively charged and neutral peptides ablate HSPG binding. 37 Both the CAP and CNH peptides have a net positive charge as they contain 1 and 2 basic amino acids, respectively. Modelling to predict the conformation of the peptides within the AAV2 capsid, suggests ways in which the HSPG binding site could be formed with and without the formation of a disulphide bond between the two cysteine residues of the peptides (Figure 1 ). This may enable both of these AAV2 vectors to maintain an ability to bind heparin despite the disruption of the original binding site in the capsid. To further enhance the detargeting of these vectors, the peptide insertion could have been combined with making three point mutations (the A3 vector) in the heparin binding site (R585A, N587A and R588A) that have been shown to decrease vector binding to HSPG. 37, 38 Based on the model of how the peptides might restore HSPG binding, 37 it can be speculated that making these additional mutations may prevent or limit HSPG binding, although the positive residues in the peptide may still allow the interaction. Although both mutants differ in their heparin binding ability in comparison to rAAV-RC it cannot be expected that the two mutants display the same transduction pattern. Although both targeting mutants bind heparin/HSPG it cannot be assumed that they exclusively use this pathway. Depending on the amount of target receptor that is displayed on the cell surface and/or the affinity of the ligand towards its target receptor, target receptor specific transduction should be observed that may differ between the two different vectors. In addition, the two vectors bind to different target receptors which may result in differences with regard to efficiency of cell entry and/or intracellular processing and thus to differences in transduction ability.
Although one of the main advantages of biopanning is that it can be used to identify targeting peptides without the requirement for prior knowledge of a specific molecular target, this has created problems with the further development and characterization of the peptides used in targeting viral vectors. In most published examples where peptides have been used to retarget viral vectors for gene therapy, there has been very little attempt to elucidate the novel receptor that the virus is utilizing. Identifying the receptors for these vectors may be advantageous in the development of the vector by providing additional information about the tropism and specificity of the vector and may highlight any potential problems with species specificity of the vector. It would also be advantageous for developing an accurate safety profile of the modified viruses. As the CNH peptide has homology to TIMP2, 13 it was thought that MT1-MMP could act as a receptor for the CNH modified viruses. In vitro results suggested AAV2-CNH bound MT1-MMP, and SPR confirmed this.
Infection of the mouse endothelial cells in the presence of the proteasome inhibitors MG132 and LnLL showed significant enhancement of the transduction of both AAV2-RC and AAV2-CAP, whereas AAV2-CNH was less affected. This suggests that AAV2-CNH might use an alternative mechanism for trafficking to the nucleus that reduces virus degradation by the ubiquitin-proteasome pathway. Whereas AAV2-CAP may be entering cells but producing limited transgene expression due to degradation of the virus before it reaches the nucleus. This demonstrates not only the importance of the initial receptor binding interaction, but also the effect of capsid modifications on the later stages of transduction.
Despite the possible inefficiency of AAV2-CAP in vitro, in vivo both AAV2-CAP and AAV2-CNH seem to be retargeted to the BCA and aorta of ApoEÀ/À mice with atherosclerosis and compared to AAV2-RC they were detargeted from all other tissues examined. It is interesting to note that despite the peptide-modified viruses retaining the capacity to bind HSPG, both AAV2-CAP and AAV2-CNH were to some extent detargeted from the liver and spleen. The in vivo results therefore suggest that both AAV2-CAP and AAV2-CNH provide vectors that are detargeted from the native AAV2 tropism and retargeted to areas of the vasculature in mice with atherosclerosis.
In summary, incorporation of the atherosclerotic plaque-targeting peptides, CAP and CNH, into the capsid of AAV2 produced vectors mediated a higher level of transduction of atherosclerotic vasculature than unmodified AAV2. For AAV2-CNH, the in vitro results were particularly good as it produced enhanced transduction of all the vascular cells, but not HeLa cells and it may traffic to the nucleus via a pathway that avoids degradation by the ubiquitin-proteasome pathway. The in vivo results with both AAV2-CAP and AAV2-CNH were very encouraging, as they suggest that the native tropism of the virus has been greatly reduced and the viruses have been retargeted to areas of the vasculature where atherosclerosis is known to occur. However, for both AAV2-CAP and AAV2-CNH some ability to bind heparin has been maintained, although by incorporation of further detargeting mutations it may be possible to reduce this and produce efficiently retargeted vectors. As atherosclerosis is a chronic condition it is likely that relatively long-term gene expression will be required. Previous studies have shown this can be achieved using AAV2 based vectors. 39, 40 Therefore the AAV2 vector platform provides an optimal vector for targeted gene delivery to atherosclerotic plaques.
Materials and methods
Unless otherwise stated all chemicals were obtained from Sigma (Poole, UK) and cell culture reagents were obtained from Invitrogen (Paisley, Scotland, UK). HSVEC were prepared as described. 41 
AAV2 production and titering
Peptide-modified AAV2 vectors were generated as previously described. 11 Overlapping oligonucleotides encoding the peptides CAP (5 0 -CGCGTCGTGTGCTCC CGGGCCTTCTAAGTCATGCG-3 0 and 5 0 -CGCGCGCAT GACTTAGAAGGCCCGGGAGCACACGA-3 0 ) and CNH (5 0 -CGCGTCGTGCAACCATCGATACATGCAGATGTG CG-3 0 and 5 0 -CGCGCGCACATCTGCATGTATCGATGG TTGCACGA-3 0 ) were annealed and inserted into the MluI-AscI site of the helper plasmid pRC99 to produce pRCcap and pRCcnh, which express the peptide sequence after residue 587 of the AAV-2 capsid. pRC99 was generated by inserting the overlapping sequence of the three restriction enzymes MluI, BspEI and AscI into the amino acid position 587 of the AAV2 capsid cloned in pRCwt (16) . A total of 293 cells at 80% confluence were cotransfected with 37.5 mg of pZnL (encodes the AAV ITRs flanking the LacZ reporter gene and a CMV promoter 10 ) the pRC plasmid (for the production of AAV2 with unmodified capsid) or with pRCcap or pRCcnh (for the production of the respective targeting vector), and pXX6 (provides the adenovirus genes required for helper function) at a 1:1:1 molar ratio. Viruses expressing the self-complementary eGFP gene were produced using the plasmid pscAGFPFG2 (which contains the eGFP flanked by AAV2 ITRs) instead of pZnL. After 48 h cells were harvested and pelleted by centrifugation. Cells were resuspended in 150 mmol l À1 NaCl, 50 mmol l À1 Tris-HCl (pH 8.5), freeze-thawed three times and treated with benzonase (50 U ml À1 for 30 min at 37 1C). Cell debris was removed by centrifugation, and supernatant was loaded onto an iodixanol gradient as described and subjected to centrifugation at 69 000 rpm for 1 h at 18 1C, and the resulting 40% iodixanol phase containing AAV vectors was harvested. Genome titres of AAV-RC, AAV-CAP and AAV-CNH were calculated by real-time PCR.
Heparin binding of AAV2 vectors
AAV2 vectors were loaded onto HiTrap Heparin HP (Amersham Bioscience, Buckinghamshire, UK), and the initial flowthrough was collected. The column was washed twice with phosphate-buffered saline (PBS) containing 1 mM MgCl 2 , 2.5 mM KCl and then bound virus was eluted by applying two 5 ml aliquots of PBS containing 1 mM MgCl 2 , 2.5 mM KCl, 1 M NaCl. The virus content of each of the fractions was analysed by real-time PCR.
In vitro infections
Cells were exposed to a multiplicity of infection (MOI) of 1000 for 24 h at 37 1C. Cells were washed in PBS then placed in fresh media and incubated for 48 h before transgene expression was measured. For all in vitro transduction experiments, cells were washed in PBS then lysed in 80 ml 0.2% (v/v) Triton X-100 in PBS. LacZ expression was quantified using the Galacto-Light Plus chemiluminescence assay (Tropix, Bedford, MA, USA) as described by the manufacturer. Levels were normalized to total protein concentration using the BCA assay (Pierce, Cramlington, Northumberland, UK).
To further analyse the transduction of the AAV vectors, cells were infected with an MOI of 1000 for 24 h in the presence or absence of 1 U of heparin per 1 Â 10 6 gp, 40 mM LnLL (Calbiochem, Merck Biosciences Ltd, Nottingham, UK) or 4 mM MG132 (Calbiochem, Merck Biosciences Ltd). Cells were washed in PBS then incubated in fresh media for 48 h.
Surface plasmon resonance analysis
Surface plasmon resonance experiments were performed using a Biacore X instrument (Biacore, Stevenage, UK). Human MT1-MMP 42 was covalently immobilized onto a CM5 biosensor chip according to the manufacturer's instructions. Virus was passed over the chip at a flow rate of 20 ml min
À1
.
In vivo transduction
ApoEÀ/À C57Bl6 mice were maintained on a high fat diet containing 21% beef lard supplemented with 0.15% cholesterol for 12 weeks from the age of 6 weeks. Following tail vein injection of 6 Â 10 9 gp of the vectors (with eGFP transgene) mice were maintained for a further 28 days. Mice were then perfused with PBS, organs and blood vessels (whole aorta) were harvested and snap-frozen. DNA was extracted from tissues using the QIAamp DNA mini kit (Qiagen, Crawley, West Sussex, UK) as per the manufacturer's instructions. DNA in each sample was measured using the ND1000 Spectrophotometer (Nanodrop, Labtech, Ringmer, East Sussex, UK).
For detection of the eGFP vectors the SYBR green PCR kit (Applied Biosystems, Foster City, CA, USA) was used with 300 nM forward (5 0 -CTCGATGTTGTGGCGGAT-3 0 ) and reverse primers (5 0 -GCGCCGAGGTGAAGTT-3 0 ). In each Taqman reaction, 100 ng DNA was used. A standard curve was produced from serial dilutions of the virus. All samples and standards were analysed in duplicate. The cycle conditions used were: step 1, 95 1C for 10 min; step 2, 95 1C for 15 s 60 1C for 1 min repeated for 50 cycles; step 3, 95 1C for 15 s, 60 1C for 15 s and 95 1C for 15 s. Results were analysed using Taqman data analysis software (Applied Biosystems).
Statistical analysis
All data were analysed by unpaired Student's t-test and are shown as mean ± standard error of the mean (s.e.m.). Data were considered significant when Po0.05.
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